FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024962747> ?p ?o ?g. }

• W2024962747 endingPage "340" @default.
• W2024962747 startingPage "331" @default.
• W2024962747 abstract "Six patients with Parkinson's disease and refractory motor fluctuations, with severe subcutaneous (s.c.) nodule formation as a result of long-term s.c. apomorphine infusions, were switched to intravenous (i.v.) therapy via a long-term in-dwelling venous catheter. Five patients were followed-up for a mean of 7 months (range 0.5-18 months). All patients had plasma apomorphine concentrations measured at baseline during s.c. infusions and three had follow-up measurements when stabilized on i.v. therapy, to test the hypothesis that motor fluctuations in these patients are largely due to impaired absorption of apomorphine. The mean i.v. rate of 9.0 mg/h (range 5-14 mg) and 24-h dose of 256.7 mg (range 90-456 mg) of apomorphine were not significantly reduced compared with the s.c. route (9.24 mg/h and 243.4 mg). However, additional oral anti-parkinsonian medication was reduced by a mean of 59%, and 'off' time was virtually eliminated (mean reduction from 5.4 to 0.5 h per day, P< 0.05). There was also a significant reduction in dyskinesias and markedly improved quality of life. Pharmacokinetic analysis demonstrated more reliable and smoother delivery of apomorphine via the i.v. route, although 'off' periods were not always explained by low plasma apomorphine concentrations. Complication rates were high and included three unforeseen hazardous intravascular thrombotic complications, secondary to apomorphine crystal accumulation, necessitating cardiothoracic surgery. We conclude that i.v. apomorphine therapy holds promise as a more effective way of controlling motor fluctuations than the s.c. route. However, further preclinical research is required before i.v. Britaject apomorphine can be recommended for routine clinical practice. Even when stable plasma apomorphine concentrations were achieved, motor fluctuations could not be totally eradicated, suggesting that postsynaptic receptor changes may also play a role in the refractory 'off' periods in these patients." @default.
• W2024962747 created "2016-06-24" @default.
• W2024962747 creator A5009222694 @default.
• W2024962747 creator A5026136994 @default.
• W2024962747 creator A5037990955 @default.
• W2024962747 creator A5038028584 @default.
• W2024962747 creator A5040738183 @default.
• W2024962747 creator A5057077030 @default.
• W2024962747 creator A5063335320 @default.
• W2024962747 date "2001-02-01" @default.
• W2024962747 modified "2023-09-26" @default.
• W2024962747 title "Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations" @default.
• W2024962747 cites W1967990636 @default.
• W2024962747 cites W1969121587 @default.
• W2024962747 cites W1975626829 @default.
• W2024962747 cites W1977112433 @default.
• W2024962747 cites W1983046432 @default.
• W2024962747 cites W1997739756 @default.
• W2024962747 cites W2000697016 @default.
• W2024962747 cites W2003858726 @default.
• W2024962747 cites W2004153344 @default.
• W2024962747 cites W2006924299 @default.
• W2024962747 cites W2008933526 @default.
• W2024962747 cites W2010255219 @default.
• W2024962747 cites W2024440004 @default.
• W2024962747 cites W2026246620 @default.
• W2024962747 cites W2030419352 @default.
• W2024962747 cites W2038912171 @default.
• W2024962747 cites W2044163045 @default.
• W2024962747 cites W2046704461 @default.
• W2024962747 cites W2047173788 @default.
• W2024962747 cites W2052737428 @default.
• W2024962747 cites W2053851028 @default.
• W2024962747 cites W2056735334 @default.
• W2024962747 cites W2059230798 @default.
• W2024962747 cites W2061530817 @default.
• W2024962747 cites W2070793498 @default.
• W2024962747 cites W2071287920 @default.
• W2024962747 cites W2071608414 @default.
• W2024962747 cites W2079806597 @default.
• W2024962747 cites W2086053110 @default.
• W2024962747 cites W2122189667 @default.
• W2024962747 cites W2130696280 @default.
• W2024962747 cites W2132528735 @default.
• W2024962747 cites W2146291656 @default.
• W2024962747 cites W2150331044 @default.
• W2024962747 cites W2152394711 @default.
• W2024962747 cites W2152767944 @default.
• W2024962747 cites W2166534380 @default.
• W2024962747 cites W2273119576 @default.
• W2024962747 cites W2298275186 @default.
• W2024962747 cites W2321544597 @default.
• W2024962747 cites W2401095344 @default.
• W2024962747 cites W2405443202 @default.
• W2024962747 cites W2414671895 @default.
• W2024962747 cites W2417706018 @default.
• W2024962747 cites W2461633631 @default.
• W2024962747 cites W2463139965 @default.
• W2024962747 cites W2551900282 @default.
• W2024962747 cites W35189200 @default.
• W2024962747 cites W63043341 @default.
• W2024962747 cites W2404715833 @default.
• W2024962747 doi "https://doi.org/10.1093/brain/124.2.331" @default.
• W2024962747 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11157560" @default.
• W2024962747 hasPublicationYear "2001" @default.
• W2024962747 type Work @default.
• W2024962747 sameAs 2024962747 @default.
• W2024962747 citedByCount "86" @default.
• W2024962747 countsByYear W20249627472012 @default.
• W2024962747 countsByYear W20249627472013 @default.
• W2024962747 countsByYear W20249627472014 @default.
• W2024962747 countsByYear W20249627472015 @default.
• W2024962747 countsByYear W20249627472016 @default.
• W2024962747 countsByYear W20249627472017 @default.
• W2024962747 countsByYear W20249627472018 @default.
• W2024962747 countsByYear W20249627472019 @default.
• W2024962747 countsByYear W20249627472020 @default.
• W2024962747 countsByYear W20249627472021 @default.
• W2024962747 countsByYear W20249627472022 @default.
• W2024962747 crossrefType "journal-article" @default.
• W2024962747 hasAuthorship W2024962747A5009222694 @default.
• W2024962747 hasAuthorship W2024962747A5026136994 @default.
• W2024962747 hasAuthorship W2024962747A5037990955 @default.
• W2024962747 hasAuthorship W2024962747A5038028584 @default.
• W2024962747 hasAuthorship W2024962747A5040738183 @default.
• W2024962747 hasAuthorship W2024962747A5057077030 @default.
• W2024962747 hasAuthorship W2024962747A5063335320 @default.
• W2024962747 hasBestOaLocation W20249627471 @default.
• W2024962747 hasConcept C112705442 @default.
• W2024962747 hasConcept C121332964 @default.
• W2024962747 hasConcept C126322002 @default.
• W2024962747 hasConcept C137183658 @default.
• W2024962747 hasConcept C141071460 @default.
• W2024962747 hasConcept C142424586 @default.
• W2024962747 hasConcept C2777525119 @default.
• W2024962747 hasConcept C2778258207 @default.
• W2024962747 hasConcept C2779134260 @default.
• W2024962747 hasConcept C2779734285 @default.

• next